| Literature DB >> 29148769 |
Christopher R Butler1, Elizabeth M Beck1, Anthony Harris2, Zhen Huang1, Laura A McAllister1, Christopher W Am Ende2, Kimberly Fennell2, Timothy L Foley2, Kari Fonseca1, Steven J Hawrylik2, Douglas S Johnson1, John D Knafels2, Scot Mente1, G Stephen Noell2, Jayvardhan Pandit2, Tracy B Phillips2, Justin R Piro1, Bruce N Rogers2, Tarek A Samad1, Jane Wang3, Shuangyi Wan3, Michael A Brodney1.
Abstract
Monoacylglycerol lipase (MAGL) is the main enzyme responsible for degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the CNS. MAGL catalyzes the conversion of 2-AG to arachidonic acid (AA), a precursor to the proinflammatory eicosannoids such as prostaglandins. Herein we describe highly efficient MAGL inhibitors, identified through a parallel medicinal chemistry approach that highlighted the improved efficiency of azetidine and piperidine-derived carbamates. The discovery and optimization of 3-substituted azetidine carbamate irreversible inhibitors of MAGL were aided by the generation of inhibitor-bound MAGL crystal structures. Compound 6, a highly efficient and selective MAGL inhibitor against recombinant enzyme and in a cellular context, was tested in vivo and shown to elevate central 2-AG levels at a 10 mg/kg dose.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29148769 DOI: 10.1021/acs.jmedchem.7b01531
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446